Clinical Trial Update: Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating Lutetium-177 dotatate in somatostatin receptor-positive advanced pulmonary neuroendocrine tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor | Phase 2 | Status: RECRUITING